2021b5550d
- Source: inbox/queue/2026-04-08-23andme-nature-glp1-pharmacogenomics.md - Domain: health - Claims: 1, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
29 lines
No EOL
2 KiB
Markdown
29 lines
No EOL
2 KiB
Markdown
# 23andMe Research Institute
|
|
|
|
**Type:** Research organization (commercial genomics company research arm)
|
|
**Founded:** Part of 23andMe, Inc. (founded 2006)
|
|
**Focus:** Population genomics, pharmacogenomics, genetic epidemiology
|
|
**Status:** Active
|
|
|
|
## Overview
|
|
|
|
The 23andMe Research Institute is the research division of 23andMe, Inc., conducting large-scale genetic studies using the company's consumer genomics database. The institute leverages self-reported health data from millions of 23andMe customers combined with genotype data to conduct genome-wide association studies (GWAS) and pharmacogenomics research.
|
|
|
|
## Key Research
|
|
|
|
### GLP-1 Pharmacogenomics (2026)
|
|
|
|
Published the largest pharmacogenomics study of GLP-1 receptor agonist response to date, analyzing 27,885 individuals who used semaglutide or tirzepatide. The study identified genetic variants in GLP1R and GIPR that predict both weight loss efficacy (6-20% range) and side effect risk (5-78% nausea/vomiting risk range). Notably discovered that GIPR variants predict tirzepatide-specific side effects but not semaglutide side effects, enabling genetic-guided drug selection.
|
|
|
|
## Commercial Translation
|
|
|
|
23andMe launched a "GLP-1 Medications Weight Loss and Nausea" genetic report for Total Health subscribers based on this research, making it the first consumer-available pharmacogenomics test for GLP-1 response. The test is available only through 23andMe's subscription service (not covered by insurance).
|
|
|
|
## Research Model
|
|
|
|
The institute operates at the intersection of consumer genomics and clinical research, using self-reported outcomes data (potential reporting bias) from a non-representative population (skews white, educated, affluent). Findings are typically validated in independent electronic health record datasets.
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-08** — Published GLP-1 pharmacogenomics study in Nature (n=27,885), identifying GLP1R and GIPR variants predicting weight loss and side effects
|
|
- **2026-04-08** — Launched commercial GLP-1 genetic testing through Total Health subscription service |